LH Labcorp
Durable lab-scale franchise, but the price already assumes margin recovery; modestly overvalued.
The story
Labcorp is the largest US clinical lab, paired with a central-lab/biopharma testing arm now that Fortrea has been spun off. It is a mature scale franchise with route density, payer contracts and the US's largest test menu, and it grows mid-single digits by buying hospital outreach businesses and adding specialty and esoteric testing. GAAP margins understate its economics because heavy acquisition amortization depresses them. Reimbursement pressure (PAMA) and labor costs cap upside, so margins should settle in the low-to-mid teens rather than return to COVID-era peaks.
Growth tracks the ~5.6% five-year CAGR plus outreach tuck-ins, then fades to 3%. The target margin moves from about 10% GAAP toward 14% because amortization runs off, the LaunchPad cost program delivers and peer Quest earns similar margins, but it stays below the roughly 15% adjusted figure to stay honest. Sales-to-capital is set at 1.8, above the 1.03 book figure that is inflated by goodwill, because incremental growth from density and tuck-ins needs less capital than the historical M&A did. Beta sits slightly below the 0.9 industry anchor because demand is defensive and non-discretionary.
Value drivers
| Revenue growth (Y1) | 6.0% |
| Terminal growth | 3.0% |
| Forecast horizon | 7y |
| Target operating margin | 14.0% |
| Years to target margin | 5 |
| Sales-to-capital | 1.80 |
| Beta | 0.85 |
| Failure probability | 2.0% |
| Cost of capital (WACC) | 8.3% |
| Terminal WACC | 8.9% |
Valuation bridge
| PV of explicit FCFF | 6.95B |
| PV of terminal value | 14.56B |
| Equity value | 16.10B |
| ÷ shares → per share | $198.23 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 15.47B | 6.0% | 10.8% | 1.32B | 486.48M | 834.63M | 770.43M |
| 2 | 16.32B | 5.5% | 11.6% | 1.50B | 472.70M | 1.03B | 873.67M |
| 3 | 17.14B | 5.0% | 12.4% | 1.68B | 453.36M | 1.23B | 966.70M |
| 4 | 17.91B | 4.5% | 13.2% | 1.87B | 428.43M | 1.44B | 1.05B |
| 5 | 18.62B | 4.0% | 14.0% | 2.07B | 397.96M | 1.67B | 1.12B |
| 6 | 19.28B | 3.5% | 14.0% | 2.14B | 362.14M | 1.78B | 1.10B |
| 7 | 19.85B | 3.0% | 14.0% | 2.20B | 321.27M | 1.88B | 1.07B |
Key risks
- PAMA Medicare fee cuts resuming and commercial payer rate pressure
- Overpaying for acquisitions, which would destroy value through low incremental ROIC
- Biopharma lab services cyclicality tied to CRO and clinical-trial funding
- Labor cost inflation squeezing margins
Catalysts
- Further PAMA delay or reform that locks in reimbursement stability
- Margin expansion from LaunchPad savings and integration of hospital outreach deals
- Recovery in central lab and early development biopharma demand